Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

Thomas Yau

Citation

Annals of Oncology (2019) 30 (suppl_9): ix42-ix67. 10.1093/annonc/mdz422

Authors

T. Yau1, T. Meyer2, R.K. Kelley3, M. Mangeshkar4, A. Cheng5, A.B. El-Khoueiry6, G.K. Abou-Alfa7

Author affiliations

  • 1 Department Of Medicine, Queen Mary Hospital, Nil - Hong Kong/HK
  • 2 Oncology, Royal Free Hospital, London/GB
  • 3 Medicine, USCSF Hellen Diller Family Comprehensive Cancer Center, 94143 - San Francisco/US
  • 4 Biostatistics, Exelixis, Alameda/US
  • 5 College Of Medicine, National Taiwan University, Taipei/TW
  • 6 Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, 90033 - Los Angeles/US
  • 7 Oncology, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 133P

Background

C improved overall survival (OS) and progression-free survival (PFS) vs P in the phase 3 CELESTIAL trial (NCT01908426). Median OS was 10.2 mo with C vs 8.0 mo with P (HR 0.76, 95% CI 0.63–0.92; p = 0.005), and median PFS was 5.2 mo vs 1.9 mo (HR 0.44, 95% CI 0.36–0.52; p < 0.001) (Abou-Alfa, NEJM 2018). Here, retrospective univariate (UV) and multivariate (MV) analyses were done to identify prognostic and predictive factors for OS from CELESTIAL.

Methods

707 patients (pts) were randomized 2:1 to receive C (60 mg qd) or P. Pts were Child-Pugh grade A and ECOG PS ≤ 1 and must have received prior sorafenib and could have received up to 2 prior lines of systemic therapy for HCC. UV and MV analyses of OS were done using the Cox proportional hazard regression model to compare subgroups defined by baseline variables within each treatment group (Bruix, J Hepatol 2017). MV analyses used backward selection with cutoffs of p ≤ 0.1 for inclusion and p ≤ 0.05 for retention of prognostic factors in the final model. Variables with p ≤ 0.05 for treatment-subgroup interaction were considered possible predictive factors for treatment benefit.

Results

Age, sex, race, region, and etiology were not significant covariates in stepwise UV and MV analyses of OS. Nine baseline variables related to disease status, laboratory values, or prior therapy were identified as possible prognostic factors for OS in one or both treatment groups (Table). No covariates were found to be predictive of an OS benefit with C.

Conclusions

Exploratory UV and MV analyses identified high baseline values of AFP, alkaline phosphatase, ALBI grade, neutrophil to lymphocyte ratio, and number of disease sites as possible prognostic factors for shorter OS in previously treated aHCC. Disease etiology and demographic factors such as race and region were not found to be prognostic for OS.Table:

133P

MV analysis of OSCabozantinibPlacebo
p-valueHRp-valueHR
ECOG PS [≥1 vs 0]0.00201.430.961.01
Macrovascular invasion (MVI) [yes vs no]0.00231.470.161.28
Number of sites [2 vs 1]0.0471.330.00241.84
Number of sites [3 vs 1]<0.00011.820.0101.70
Alpha-fetoprotein (AFP) [≥400 vs < 400 ng/mL]<0.00011.72<0.00011.95
Albumin-bilirubin (ALBI) grade [≥2 vs 1]0.00051.570.0221.48
Neutrophil to lymphocyte ratio [≥median vs 0.0121.340.0251.45
Alkaline phosphatase [≥median vs 0.00091.50<0.00012.15
Prior transarterial chemoembolization (TACE) [yes vs no]0.340.900.0280.69

Clinical trial identification

NCT01908426 (Other Study ID Numbers: XL184-309).

Editorial acknowledgement

David Markby (Exelixis).

Legal entity responsible for the study

Exelixis.

Funding

Exelixis.

Disclosure

T. Yau: Advisory / Consultancy: Exelixis; Honoraria (self): Ipen, Exelixis. T. Meyer: Advisory / Consultancy: BMS, BAYER, EISAI, BTG, AZ, BEIGENE, TARVEDA, MSD; Research grant / Funding (self): BTG BAYER. R.K. Kelley: Research grant / Funding (institution), Funding to institution: Agios, AstraZeneca, Bayer, BMS ; Research grant / Funding (self), Funding to self: IDMC: Genentech/Roche ; Research grant / Funding (institution): Agios, AstraZeneca, Bayer, BMS, Eli Lilly, Exelixis, EMD Serono, Medimmune, Merck, Novartis, QED, Taiho. M. Mangeshkar: Full / Part-time employment: Exelixis; Shareholder / Stockholder / Stock options: Exelixis. A-L. Cheng: Advisory / Consultancy, Advisory: Bayer Schering Pharma, Bristol-Myers Squibb, Eisai, Merck Serono, Novartis, Ono Pharmaceutical, Exelixis, Nucleix Ltd., Roche/Genentech, and IQVIA; Advisory / Consultancy, Consultancy: Bayer Schering Pharma, Bristol-Myers Squibb, Eisai, Merck Serono, Novartis, Ono Pharmaceutical, Exelixis, Nucleix Ltd., Roche/Genentech, and IQVIA; Honoraria (self): Bayer, Eisai, and Merck Sharp Dohme, Merck Serono, Novartis, Ono Pharmaceutical, Roche/Genentech, and IQVIA. A.B. El-Khoueiry: Advisory / Consultancy: Bayer, BMS, Agenus, Merck, EISAI, Pieris, EMD Serono, Exelixis, Roche/Genentech, Apeiron; Research grant / Funding (self): AstraZeneca, Astex. G.K. Abou-Alfa: Research grant / Funding (institution): ActaBiologica, Agios, Array, AstraZeneca, Bayer, Beigene, BMS, Casi, Celgene, Exelixis, Genentech, Halozyme, Incyte, Lilly, Mabvax, Novartis, OncoQuest, Polaris Puma, QED, Roche; Advisory / Consultancy: 3DMedcare, Agios, Alignmed, Amgen, Antengene, Aptus, Aslan, Astellas, AstraZeneca, Bayer, Beigene, Bioline, BMS, Boston Scientifc, Bridgebio, Carsgen, Celgene, Casi, Cipla, CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Flatiron, Genoscience, Halozyme.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.